[
  {
    "ts": "2026-02-09T06:00:00+00:00",
    "headline": "Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
    "summary": "BAAR, Switzerland, February 09, 2026--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
    "url": "https://finance.yahoo.com/news/evinova-bristol-myers-squibb-forge-060000425.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "2c90927b-445d-31c1-bbf9-e48db3de11c5",
      "content": {
        "id": "2c90927b-445d-31c1-bbf9-e48db3de11c5",
        "contentType": "STORY",
        "title": "Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
        "description": "",
        "summary": "BAAR, Switzerland, February 09, 2026--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence",
        "pubDate": "2026-02-09T06:00:00Z",
        "displayTime": "2026-02-09T06:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/4d2e1496798a9683f9ff6f798b89c932",
          "originalWidth": 1858,
          "originalHeight": 417,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IAU6g1IHPac3antWej87tg--~B/aD00MTc7dz0xODU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4d2e1496798a9683f9ff6f798b89c932.cf.webp",
              "width": 1858,
              "height": 417,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dXgICgHdbUgudIAeI5bJpg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4d2e1496798a9683f9ff6f798b89c932.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evinova-bristol-myers-squibb-forge-060000425.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evinova-bristol-myers-squibb-forge-060000425.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T13:33:57+00:00",
    "headline": "Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Most Profitable Undervalued Stocks to Buy On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated probability of success for iber/mezi to 90% from 33% and lifted its […]",
    "url": "https://finance.yahoo.com/news/guggenheim-raises-price-target-bristol-133357957.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4e73a4f8-59f1-3b5b-abed-19dbbbe23e36",
      "content": {
        "id": "4e73a4f8-59f1-3b5b-abed-19dbbbe23e36",
        "contentType": "STORY",
        "title": "Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Most Profitable Undervalued Stocks to Buy On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated probability of success for iber/mezi to 90% from 33% and lifted its […]",
        "pubDate": "2026-02-09T13:33:57Z",
        "displayTime": "2026-02-09T13:33:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-raises-price-target-bristol-133357957.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-raises-price-target-bristol-133357957.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T15:29:00+00:00",
    "headline": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
    "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
    "url": "https://finance.yahoo.com/news/bmy-7-6-post-q4-152900297.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "95cd449c-45e5-3736-b5e6-fd536367ef1f",
      "content": {
        "id": "95cd449c-45e5-3736-b5e6-fd536367ef1f",
        "contentType": "STORY",
        "title": "BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.",
        "pubDate": "2026-02-09T15:29:00Z",
        "displayTime": "2026-02-09T15:29:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmy-7-6-post-q4-152900297.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmy-7-6-post-q4-152900297.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T23:14:50+00:00",
    "headline": "Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism",
    "summary": "Earnings-triggered move in Bristol-Myers Squibb stock Bristol-Myers Squibb (BMY) is back in focus after its latest earnings release, which showed higher profitability, flat full year revenue, and guidance that came in above analyst expectations. See our latest analysis for Bristol-Myers Squibb. The recent earnings release, analyst upgrades around key pipeline drugs, and news of AI-enabled clinical trial work have all fed into a sharp rebound. A 24.73% 90 day share price return and a 5 year...",
    "url": "https://finance.yahoo.com/news/assessing-bristol-myers-squibb-bmy-231450195.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c08f3f57-f640-36fc-a30a-ea50ea76b8ce",
      "content": {
        "id": "c08f3f57-f640-36fc-a30a-ea50ea76b8ce",
        "contentType": "STORY",
        "title": "Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism",
        "description": "",
        "summary": "Earnings-triggered move in Bristol-Myers Squibb stock Bristol-Myers Squibb (BMY) is back in focus after its latest earnings release, which showed higher profitability, flat full year revenue, and guidance that came in above analyst expectations. See our latest analysis for Bristol-Myers Squibb. The recent earnings release, analyst upgrades around key pipeline drugs, and news of AI-enabled clinical trial work have all fed into a sharp rebound. A 24.73% 90 day share price return and a 5 year...",
        "pubDate": "2026-02-09T23:14:50Z",
        "displayTime": "2026-02-09T23:14:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-bristol-myers-squibb-bmy-231450195.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-bristol-myers-squibb-bmy-231450195.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]